- 15 percent of immunosuppressed patients with sepsis died during hospitalization compared to 12 percent of non-immunosuppressed patients with sepsis at all hospitals.
- At hospitals seeing fewer than 225 immunosuppressed patients with sepsis each year, these patients were 38 percent more likely to die while hospitalized, compared to 21 percent more likely to die at hospitals that saw 225 or more of these patients yearly.
- Above 225, caring for greater numbers of immunosuppressed patients with sepsis (one hospital treated 1,056 such patients) did not appear to reduce mortality.
- Immunosuppressed patients with sepsis were more likely than non- immunosuppressed patients to return to their homes after discharge, rather than another health facility, 60 percent vs. 50 percent, respectively.
Immunosuppressed patients with sepsis appear more likely to die if they are treated in a hospital caring for a relatively small number of these patients, according to new research published online in the Annals of the American Thoracic Society. Sepsis, a leading cause of death in U.S. hospitals, occurs when the body produces an out-of-control inflammatory response to infection.In “Hospital Volume of Immunosuppressed Sepsis Patients and Sepsis Mortality,” Jared A. Greenberg, MD, MSc, and coauthors analyzed the medical records of 350,183 patients with sepsis at 60 U.S. hospitals. One of five of those patients was classified as being immunocompromised based on being HIV-positive or having an intrinsic immune disorder, having a blood cancer or being prescribed an immunosuppressive drug for certain medical conditions while hospitalized. “While there is a lot of focus on improving sepsis outcomes through early interventions, some patients have poor outcomes from sepsis because their chronic medical conditions may worsen after the initial infectious insult,” said Dr. Greenberg, an assistant professor and critical care physician at Rush University Medical Center in Chicago, Illinois. “We hypothesized that septic patients who are immunocompromised may have improved outcomes if they are managed at hospitals that have the most experience managing immunocompromising conditions.” The study found: